Animal models for the evaluation of antipsychotic agents.
conditioned avoidance response
latent inhibition
neurodevelopmental models
pre-pulse inhibition
schizophrenia
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
revised:
04
10
2022
received:
24
12
2021
accepted:
19
11
2022
medline:
12
5
2023
pubmed:
22
11
2022
entrez:
21
11
2022
Statut:
ppublish
Résumé
Schizophrenia, the most serious among psychoses, has negative symptoms such as anhedonia, avolition and apathy, and cognitive defects in addition to positive symptoms such as hallucinations and delusions characterising all psychotic disorders. Traditional antipsychotics had dopamine D
Substances chimiques
Antipsychotic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
447-460Informations de copyright
© 2022 Société Française de Pharmacologie et de Thérapeutique. Published by John Wiley & Sons Ltd.
Références
Meyer JM. Pharmacotherapy of Psychosis and Mania. In: Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Goodman & Gilman's: The pharmacological basis of therapeutics. 13th ed. McGraw-Hill Education; 2017. Accessed September 6, 2021. accessmedicine.mhmedical.com/content.aspx?aid=1162535494
Lieberman JA, Bymaster FP, Meltzer HY, et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev. 2008;60(3):358-403. doi:10.1124/pr.107.00107
Wadenberg ML, Hicks PB. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev. 1999;23(6):851-862. doi:10.1016/s0149-7634(99)00037-8
Castagné V, Moser PC, Porsolt RD. Preclinical behavioral models for predicting antipsychotic activity. Adv Pharmacol San Diego Calif. 2009;57:381-418. doi:10.1016/S1054-3589(08)57010-4
van der Staay FJ, Arndt SS, Nordquist RE. Evaluation of animal models of neurobehavioral disorders. Behav Brain Funct. 2009;5(1):11. doi:10.1186/1744-9081-5-11
Wadenberg MLG. Conditioned avoidance response in the development of new antipsychotics. Curr Pharm des. 2010;16(3):358-370. doi:10.2174/138161210790170085
Meisenzahl EM, Schmitt GJ, Scheuerecker J, Möller HJ. The role of dopamine for the pathophysiology of schizophrenia. Int Rev Psychiatry Abingdon Engl. 2007;19(4):337-345. doi:10.1080/09540260701502468
Gobira PH, Ropke J, Aguiar DC, Crippa JAS, Moreira FA. Animal models for predicting the efficacy and side effects of antipsychotic drugs. Rev Bras Psiquiatr. 2013;35(suppl 2):S132-S139. doi:10.1590/1516-4446-2013-1164
Vogel H. Psychotropic and Neurotropic Activity. In: 2007:565-876. 10.1007/978-3-540-70995-4_6
Sánchez JPB, Ellenbroek BA. Preclinical Effects of Antipsychotic Drugs. In: Nielsen S, Bruno R, Schenk S, eds. Non-medical and illicit use of psychoactive drugs. Current Topics in Behavioral Neurosciences. Vol.34. Springer International Publishing; 2016:1-16. doi:10.1007/7854_2016_447
Hoffman DC, Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl). 1995;120(2):128-133. doi:10.1007/BF02246184
Weiner I, Gaisler I, Schiller D, Green A, Zuckerman L, Joel D. Screening of antipsychotic drugs in animal models. Drug Dev Res. 2000;50(3-4):235-249. doi:10.1002/1098-2299%28200007%2F08%2950:3%2F4%3C235::AID%2DDDR7%3E3.0.CO;2%2DR
Dunn LA, Atwater GE, Kilts CD. Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioral model of clinical drug action. Psychopharmacology (Berl). 1993;112(2-3):315-323. doi:10.1007/BF02244927
Moser PC, Hitchcock JM, Lister S, Moran PM. The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res Brain Res Rev. 2000;33(2-3):275-307. doi:10.1016/s0165-0173(00)00026-6
Noda Y, Kamei H, Mamiya T, Furukawa H, Nabeshima T. Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions. Neuropsychopharmacology. 2000;23(4):375-387. doi:10.1016/S0893-133X(00)00138-X
Nabeshima T, Mouri A, Murai R, Noda Y. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine. Ann N Y Acad Sci. 2006;1086(1):160-168. doi:10.1196/annals.1377.003
Neves G, Borsoi M, Antonio CB, Pranke MA, Betti AH, Rates SMK. Is forced swimming immobility a good endpoint for modeling negative symptoms of schizophrenia? - study of sub-anesthetic ketamine repeated administration effects. An Acad Bras Ciênc. 2017;89(3):1655-1669. doi:10.1590/0001-3765201720160844
Costall B, Naylor RJ, Nohria V. Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity. Eur J Pharmacol. 1978;50(1):39-50. doi:10.1016/0014-2999(78)90251-0
Hoffman HS, Ison JR. Reflex modification in the domain of startle: I. some empirical findings and their implications for how the nervous system processes sensory input. Psychol Rev. 1980;87(2):175-189. doi:10.1037/0033-295X.87.2.175
Neves G, Antonio CB, Betti AH, et al. New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia. Behav Brain Res. 2013;237:86-95. doi:10.1016/j.bbr.2012.09.016
Swerdlow NR. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry. 1994;51(2):139-154. doi:10.1001/archpsyc.1994.03950020063007
Swerdlow NR, Geyer MA. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull. 1998;24(2):285-301. doi:10.1093/oxfordjournals.schbul.a033326
Betti AH, Antonio CB, Pompeu TET, et al. LASSBio-1422: a new molecular scaffold with efficacy in animal models of schizophrenia and disorders of attention and cognition. Behav Pharmacol. 2017;28(1):48-62. doi:10.1097/FBP.0000000000000267
Neill JC, Barnes S, Cook S, et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther. 2010;128(3):419-432. doi:10.1016/j.pharmthera.2010.07.004
Becker A, Grecksch G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(8):1267-1277. doi:10.1016/j.pnpbp.2004.06.019
Karasawa JI, Hashimoto K, Chaki S. D-serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res. 2008;186(1):78-83. doi:10.1016/j.bbr.2007.07.033
Pichat P, Bergis OE, Terranova JP, et al. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacol off Publ am Coll Neuropsychopharmacol. 2007;32(1):17-34. doi:10.1038/sj.npp.1301188
Idris NF, Repeto P, Neill JC, Large CH. Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat. Psychopharmacology (Berl). 2005;179(2):336-348. doi:10.1007/s00213-004-2058-5
Chudasama Y, Robbins TW. Psychopharmacological approaches to modulating attention in the five-choice serial reaction time task: implications for schizophrenia. Psychopharmacology (Berl). 2004;174(1):86-98. doi:10.1007/s00213-004-1805-y
Lipska BK, Jaskiw GE, Weinberger DR. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacol off Publ am Coll Neuropsychopharmacol. 1993;9(1):67-75. doi:10.1038/npp.1993.44
Lipska BK, Swerdlow NR, Geyer MA, Jaskiw GE, Braff DL, Weinberger DR. Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology (Berl). 1995;122(1):35-43. doi:10.1007/BF02246439
Al-Amin HA, Weinberger DR, Lipska BK. Exaggerated MK-801-induced motor hyperactivity in rats with the neonatal lesion of the ventral hippocampus. Behav Pharmacol. 2000;11(3-4):269-278. doi:10.1097/00008877-200006000-00010
Fabricius K, Helboe L, Fink-Jensen A, Wörtwein G, Steiniger-Brach B. Pharmacological characterization of social isolation-induced hyperactivity. Psychopharmacology (Berl). 2011;215(2):257-266. doi:10.1007/s00213-010-2128-9
Jones CA, Brown AM, Auer DP, Fone KCF. The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat. Psychopharmacology (Berl). 2011;214(1):269-283. doi:10.1007/s00213-010-1931-7
Shigemi K, Tsuneyoshi Y, Yamada S, et al. Oral administration of L-serine reduces the locomotor activity of socially isolated rats. Neurosci Lett. 2010;468(1):75-79. doi:10.1016/j.neulet.2009.10.068
Cilia J, Reavill C, Hagan J, Jones D. Long-term evaluation of isolation-rearing induced prepulse inhibition deficits in rats. Psychopharmacology (Berl). 2001;156(2):327-337. doi:10.1007/s002130100786
Geyer MA, Wilkinson LS, Humby T, Robbins TW. Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biol Psychiatry. 1993;34(6):361-372. doi:10.1016/0006-3223(93)90180-l
Cilia J, Cluderay JE, Robbins MJ, et al. Reversal of isolation-rearing-induced PPI deficits by an alpha7 nicotinic receptor agonist. Psychopharmacology (Berl). 2005;182(2):214-219. doi:10.1007/s00213-005-0069-5
Geyer MA, Krebs-Thomson K, Varty GB. The effects of M100907 in pharmacological and developmental animal models of Prepulse inhibition deficits in schizophrenia. Neuropsychopharmacology. 1999;21(2):S134-S142. doi:10.1016/S0893-133X(99)00123-2
Li N, Wu X, Li L. Chronic administration of clozapine alleviates reversal-learning impairment in isolation-reared rats. Behav Pharmacol. 2007;18(2):135-145. doi:10.1097/FBP.0b013e3280d3ee83
McLean S, Grayson B, Harris M, Protheroe C, Woolley M, Neill J. Isolation rearing impairs novel object recognition and attentional set shifting performance in female rats. J Psychopharmacol Oxf Engl. 2010;24(1):57-63. doi:10.1177/0269881108093842
Moore H, Jentsch JD, Ghajarnia M, Geyer MA, Grace AA. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry. 2006;60(3):253-264. doi:10.1016/j.biopsych.2006.01.003
Black MD, Simmonds J, Senyah Y, Wettstein JG. Neonatal nitric oxide synthase inhibition: social interaction deficits in adulthood and reversal by antipsychotic drugs. Neuropharmacology. 2002;42(3):414-420. doi:10.1016/s0028-3908(01)00180-0
Lipska B. To model a psychiatric disorder in animals schizophrenia as a reality test. Neuropsychopharmacology. 2000;23(3):223-239. doi:10.1016/S0893-133X(00)00137-8
Cotter D, Takei N, Farrell M, et al. Does prenatal exposure to influenza in mice induce pyramidal cell disarray in the dorsal hippocampus? Schizophr Res. 1995;16(3):233-241. doi:10.1016/0920-9964(94)e0082-i
Pearce BD, Steffensen SC, Paoletti AD, Henriksen SJ, Buchmeier MJ. Persistent dentate granule cell hyperexcitability after neonatal infection with lymphocytic choriomeningitis virus. J Neurosci off J Soc Neurosci. 1996;16(1):220-228. doi:10.1523/JNEUROSCI.16-01-00220.1996
Meyer U, Spoerri E, Yee BK, Schwarz MJ, Feldon J. Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia. Schizophr Bull. 2010;36(3):607-623. doi:10.1093/schbul/sbn131
Carreño F, Helfer VE, Staudt KJ, et al. Quetiapine lipid core nanocapsules restore prepulse inhibition deficits in a neurodevelopmental model of schizophrenia in male and female rats. Schizophr Res. 2020;218:173-179. doi:10.1016/j.schres.2020.01.007
Pletnikov MV, Ayhan Y, Nikolskaia O, et al. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol Psychiatry. 2008;13(2):173-186. doi:10.1038/sj.mp.4002079
Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci. 2008;9(6):437-452. doi:10.1038/nrn2392
Feng YQ, Zhou ZY, He X, et al. Dysbindin deficiency in sandy mice causes reduction of snapin and displays behaviors related to schizophrenia. Schizophr Res. 2008;106(2-3):218-228. doi:10.1016/j.schres.2008.07.018
Papaleo F, Yang F, Garcia S, et al. Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways. Mol Psychiatry. 2012;17(1):85-98. doi:10.1038/mp.2010.106
Gainetdinov RR, Mohn AR, Caron MG. Genetic animal models: focus on schizophrenia. Trends Neurosci. 2001;24(9):527-533. doi:10.1016/S0166-2236(00)01886-5
Ellenbroek B, Geyer M, Cools A. The behavior of APO-SUS rats in animal models with construct validity for schizophrenia. J Neurosci. 1995;15(11):7604-7611. doi:10.1523/JNEUROSCI.15-11-07604.1995
Moreno JL, González-Maeso J. Preclinical models of antipsychotic drug action. Int J Neuropsychopharmacol. 2013;16(10):2131-2144. doi:10.1017/S1461145713000606